NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2019-12-31
2018-12-31
2017-12-31
2016-12-31
Total Revenue
7,049
7,748
6,500
0
0
Cost of Revenue
78
70
-
-
-
Gross Profit
6,971
7,678
-
-
-
Operating Expenses
Research Development
23,821
26,415
82,288
49,615
47,994
Selling General and Administrative
65,101
62,485
41,743
29,472
13,436
Total Operating Expenses
87,404
87,167
120,875
73,768
55,047
Operating Income or Loss
-80,433
-79,489
-114,375
-73,768
-55,047
Interest Expense
3,769
3,644
133
43
75
Total Other Income/Expenses Net
-1,814
215
-272
492
-783
Income Before Tax
-85,707
-82,663
-114,731
-73,001
-55,562
Income Tax Expense
99
101
49
1,355
-672
Income from Continuing Operations
-85,806
-82,764
-114,780
-74,356
-54,890
Net Income
-85,806
-82,764
-114,780
-74,356
-54,890
Net Income available to common shareholders
-85,806
-82,764
-114,780
-74,356
-54,890
Basic EPS
-
-1.12
-2.26
-2.49
-2.56
Diluted EPS
-
-1.12
-2.26
-2.49
-2.56
Basic Average Shares
-
74,199
50,796
29,831
21,478
Diluted Average Shares
-
74,199
50,796
29,831
21,478
EBITDA
-
-78,249
-114,088
-72,526
-55,254